[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]
Fırat Tıp Dergisi
2009, Cilt 14, Sayı 3, Sayfa(lar) 171-174
[ Turkish ] [ Tam Metin ] [ PDF ]
Effect of Doxazosin on Prostatic Resistive Index in Patients with Benign Prostate Hyperplasia
Cüneyt ÖZDEN1, İsa GÜNAY1, Tağmaç DEREN2, Süleyman BULUT1, Süha KOPARAL2, Ali MEMİŞ1
1Ankara Numune Eğitim ve Araştırma Hastanesi, 1. Üroloji Kliniği, ANKARA, Türkiye
2Ankara Numune Eğitim ve Araştırma Hastanesi, Radyoloji Kliniği, ANKARA, Türkiye

Objective: In recent years several studies revealed that prostatic resistive index (RI) was increased on power Doppler imaging (PDI) in patients with benign prostate hyperplasia (BPH). In the present study we aimed to evaluate the effect of Doxazosin on prostatic RI in BPH patients.

Materials and Methods: Forty BPH patients with lower urinary tract symptoms included in this study. All patients received 8mg Doxazosin daily for six months. International prostatic symptom scores (IPSS), maximal urine flow rates (Qmax), total prostate volumes and prostatic RI determination with PDI were compared before and after the treatment.

Results: The mean age, IPSS and Qmax of the patients was 60.2±2 years, 20.3±4.5 and 11.3±3.0 mL/s respectively. There was a positive correlation between prostatic RI, total prostate volume and IPSS before the treatment (r=0.37 p=0.02 and r=0.40 p=0.017, respectively). On the other hand there was a negative correlation between prostatic RI and Qmax values (r= -0.38 p=0.021). There was a significant improvement in IPSS scores and Qmax values after the treatment (7.9±5.3 and 16.8±5.8 mL/s respectively, p<0.05). It was demonstrated that prostatic RI of the patients significantly decreased when compared to pretreatment levels (0.74±0.06 and 0.69±0.05 respectively, p<0.05).

Conclusion: Our data demonstrated that Doxazosin treatment significantly decreased prostatic RI of the patients with BPH. We believe that prostatic RI could be a useful parameter for the follow-up of patients receiving medical treatment with BPH.


[ Turkish ] [ Tam Metin ] [ PDF ]
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]